The estimated Net Worth of Fred Hassan is at least $326 Million dollars as of 9 March 2024. Mr. Hassan owns over 106,837 units of AMGEN stock worth over $325,287,354 and over the last 22 years he sold AMGN stock worth over $0. In addition, he makes $343,614 as Independent Director at AMGEN.
Fred has made over 15 trades of the AMGEN stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 106,837 units of AMGN stock worth $35,254,073 on 9 March 2024.
The largest trade he's ever made was buying 570,345 units of AMGEN stock on 14 August 2023 worth over $998,104. On average, Fred trades about 14,587 units every 83 days since 2003. As of 9 March 2024 he still owns at least 985,779 units of AMGEN stock.
You can see the complete history of Mr. Hassan stock trades at the bottom of the page.
Fred Hassan serves as Independent Director of the Company. Hassan is Director at Warburg Pincus LLC, a global private equity investment institution, since 2018. Mr. Hassan was Special Limited Partner at Warburg Pincus LLC from 2017 to 2018 and Partner and Managing Director from 2011 to 2017 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of Pharmacia Corporation, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of Pharmacia Corporation from its creation in 2000 as a result of the merger of Pharmacia & Upjohn, Inc. with Monsanto Company. He was President and Chief Executive Officer of Pharmacia & Upjohn, Inc. beginning in 1997. Mr. Hassan previously held senior positions with Wyeth (formerly known as American Home Products), including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at Sandoz Pharmaceuticals and headed its U.S. pharmaceuticals businesses. Mr. Hassan has been a director of Intrexon Corporation, a synthetic biology company, since 2016, serving on its Compensation Committee. Mr. Hassan was a director of Time Warner Inc., a media company, from 2009 until its acquisition by AT&T Inc., a provider of communications and digital entertainment services, in 2018. Mr. Hassan was a director of Avon Products, Inc., a manufacturer and marketer of beauty and related products, from 1999 until 2013 and served on its Compensation and Management Development, Nominating and Corporate Governance and Audit Committees, as lead independent director from 2009 to 2012, and Chairman of the Board between January and April 2013. Mr. Hassan was Chairman of the Board of Bausch & Lomb, from 2010 until its a
As the Independent Director of AMGEN, the total compensation of Fred Hassan at AMGEN is $343,614. There are 15 executives at AMGEN getting paid more, with Robert Bradway having the highest compensation of $19,612,800.
Fred Hassan is 74, he's been the Independent Director of AMGEN since 2015. There are no older and 26 younger executives at AMGEN.
Fred's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 22 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer, and Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
AMGEN executives and other stock owners filed with the SEC include: